Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA1 | P30542 | 18/20 | 0.53 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.53 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.45 |
| ▸ | ELAVL1 | Q15717 | 1/20 | 0.45 |
| ▸ | HTR1B | P28222 | 1/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.44 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL923486 | 1.00 | ADORA1 (0.53) | ADORA1SLC6A3ADORA2BELAVL1HTR1B | |
| SCHEMBL12907863 | 0.92 | ADORA1 (0.45) | ADORA1SLC6A3ADORA2BELAVL1HTR1B | |
| SCHEMBL924571 | 0.86 | ADORA1 (0.72) | ADORA1SLC6A3 | |
| SCHEMBL924572 | 0.86 | ADORA1 (0.72) | ADORA1SLC6A3 | |
| SCHEMBL923420 | 0.85 | ADORA1 (0.49) | ADORA1SLC6A3ADORA2BELAVL1HTR1B | |
| SCHEMBL923422 | 0.85 | ADORA1 (0.49) | ADORA1SLC6A3ADORA2BELAVL1HTR1B | |
| SCHEMBL1177071 | 0.84 | ADORA1 (0.70) | ADORA1SLC6A3ADORA2BELAVL1 | |
| SCHEMBL923146 | 0.83 | ADORA1 (0.54) | ADORA1SLC6A3ADORA2BHTR1BOPRK1 | |
| SCHEMBL923148 | 0.83 | ADORA1 (0.54) | ADORA1SLC6A3ADORA2BHTR1BOPRK1 | |
| SCHEMBL13285072 | 0.82 | ADORA1 (0.67) | ADORA1SLC6A3ADORA2BELAVL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021487-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2011-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021487-A1 | CYCLOALKOXY-SUBSTITUTED 4-PHENYL-3,5-DICYANOPYRIDINES AND THEIR USE | PC, DPP4, FABP3 | ADORA1 3492/4885SLC6A3 2324/4885ADORA2B 2977/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.